FRANKLIN
LAKES, N.J., Aug. 12,
2024 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
announced today that Michael Feld
has been named executive vice president and president of the Life
Sciences segment for BD, effective Aug. 20,
2024, and will serve as a member of the Executive Leadership
Team. He succeeds Dave Hickey, who
retired from BD last month after 10 years with the company.
Feld joins BD from Veralto, a spin-off of Danaher, where he was
most recently president of Hach, a global leader in water quality
products. Prior to that, Feld held several senior roles at Danaher,
including senior vice president and general manager of Cepheid
Europe, and served as president of several other Danaher businesses
including Mammotome, XOS and Dover Motion, all focused on strategic
planning, superior quality, associate development and cultural
progression.
"Mike's expertise in applying commercial and operational
excellence principles to deliver impactful results, coupled with
his experience in diagnostic solutions, position him well to lead
our Life Sciences segment," said Tom
Polen, chairman, CEO and president of BD. "As we build
momentum behind our BD Excellence operating system, Mike's
continuous improvement mindset will be an asset to BD as our Life
Sciences team continues to drive efficiencies and meaningfully
expand value for our customers, their patients and the global
healthcare ecosystem."
As president of the BD Life Sciences segment, which includes
Biosciences, Diagnostics Solutions and Specimen Management, Feld
will be responsible for an organization that is delivering
innovative advancements from discovery to diagnosis. Under his
leadership, BD Life Sciences will continue to focus on developing
solutions around smart, connected, end-to-end workflows, specimen
collection and diagnostics at new care settings, which will improve
the diagnosis and treatment of chronic conditions.
Feld earned his Bachelor of Science degree from Tulane University and his Master of Business
Administration from Northwestern
University's Kellogg School of Management.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 70,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Media:
|
Investors:
|
Troy Kirkpatrick
|
Adam Reiffe
|
VP, Public
Relations
|
Senior Director,
Investor Relations
|
858.617.2361
|
201.847.6927
|
troy.kirkpatrick@bd.com
|
adam.reiffe@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-names-michael-feld-as-president-of-life-sciences-segment-302219382.html
SOURCE BD (Becton, Dickinson and Company)